MBOT icon

Microbot Medical

4.16 USD
+0.31
8.05%
At close Aug 25, 4:00 PM EDT
Pre-market
4.27
+0.11
2.64%
1 day
8.05%
5 days
34.19%
1 month
40.07%
3 months
54.07%
6 months
173.68%
Year to date
264.91%
1 year
325.18%
5 years
-42.38%
10 years
-99.32%
 

About: Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.

Employees: 22

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

3,585% more call options, than puts

Call options by funds: $3.91M | Put options by funds: $106K

190% more capital invested

Capital invested by funds: $3.26M [Q1] → $9.43M (+$6.17M) [Q2]

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

9% more funds holding

Funds holding: 43 [Q1] → 47 (+4) [Q2]

4.07% more ownership

Funds ownership: 6.21% [Q1] → 10.28% (+4.07%) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for MBOT.

Financial journalist opinion

Based on 3 articles about MBOT published over the past 30 days

Positive
Zacks Investment Research
4 days ago
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
Neutral
GlobeNewsWire
5 days ago
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY ® System now includes 12 patents granted globally and 57 patent applications pending.
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
Neutral
GlobeNewsWire
2 weeks ago
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate).
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
Neutral
GlobeNewsWire
1 month ago
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales.
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Neutral
GlobeNewsWire
1 month ago
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, being held from July 16-20, in Strasbourg, France.
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
Neutral
GlobeNewsWire
1 month ago
Microbot Medical® Added to the Russell Microcap® Index
Automatic inclusion in the appropriate growth and value style indexes Automatic inclusion in the appropriate growth and value style indexes
Microbot Medical® Added to the Russell Microcap® Index
Neutral
GlobeNewsWire
2 months ago
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
HINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA), a key step in the Company's global IP expansion strategy.
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
Positive
Zacks Investment Research
2 months ago
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
GlobeNewsWire
2 months ago
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025.
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
Neutral
GlobeNewsWire
2 months ago
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025.
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
Charts implemented using Lightweight Charts™